Synthesis, characterization, biological evaluation, and in silico studies of novel 1,3-diaryltriazene-substituted sulfathiazole derivatives

dc.contributor.authorIsik, Mesut
dc.contributor.authorAkocak, Suleyman
dc.contributor.authorLolak, Nabih
dc.contributor.authorTaslimi, Parham
dc.contributor.authorTurkes, Cuneyt
dc.contributor.authorGülçin, İlhami
dc.contributor.authorDurgun, Mustafa
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T13:23:11Z
dc.date.created2020
dc.date.issued2020
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.description.abstractIn the present study, a series of eleven novel 1,3-diaryltriazene-substituted sulfathiazole moieties (ST1-11) was synthesized by the reaction of diazonium salt of sulfathiazole with substituted aromatic amines and their chemical structures were characterized by Fourier transform infrared,H-1-NMR (nuclear magnetic resonance),C-13-NMR, and high-resolution mass spectroscopy methods. These synthesized novel derivatives were found to be effective inhibitor molecules for alpha-glycosidase (alpha-GLY), human carbonic anhydrase (hCA), and acetylcholinesterase (AChE), withK(I)values in the range of 426.84 +/- 58.42-708.61 +/- 122.67 nM for alpha-GLY, 450.37 +/- 50.35-1,094.34 +/- 111.37 nM forhCA I, 504.37 +/- 57.22-1,205.36 +/- 195.47 nM forhCA II, and 68.28 +/- 10.26-193.74 +/- 19.75 nM for AChE. Among the synthesized novel compounds, several lead compounds were investigated against the tested metabolic enzymes. More specifically,ST11(4-[3-(perfluorophenyl)triaz-1-en-1-yl]-N-(thiazol-2-yl)benzenesulfonamide) showed a highly efficient inhibition profile againsthCA I,hCA II, and AChE, withK(I)values of 450.37 +/- 50.35, 504.37 +/- 57.22, and 68.28 +/- 10.26 nM, respectively. Due to its significant biological inhibitory potency, this derivative may be considered as an interesting lead compound against these enzymes.
dc.description.sponsorshipResearch Fund of Anadolu University [1610S681]
dc.description.sponsorshipResearch Fund of Anadolu University, Grant/Award Number: 1610S681
dc.identifier.doi10.1002/ardp.202000102
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue9
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidLolak, Nabih/0000-0003-0578-2761
dc.identifier.orcidISIK, MESUT/0000-0002-4677-8104
dc.identifier.orcidDurgun, Mustafa/0000-0003-3012-7582
dc.identifier.orcidTurkes, Cuneyt/0000-0002-2932-2789
dc.identifier.pmid32529657
dc.identifier.scopus2-s2.0-85086264431
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ardp.202000102
dc.identifier.urihttps://hdl.handle.net/11772/22731
dc.identifier.volume353
dc.identifier.wosWOS:000539602200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectEnzyme Inhibition
dc.subjectMetabolic Enzymes
dc.subjectMolecular Docking
dc.subjectSulfathiazole
dc.subjectTriazene
dc.titleSynthesis, characterization, biological evaluation, and in silico studies of novel 1,3-diaryltriazene-substituted sulfathiazole derivatives
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscoverydadfa319-65b8-4543-92b4-bea49e0139e9

Dosyalar